CN Patent

CN106543105B — 一种盐酸卡利拉嗪晶型ⅳ及其制备方法

Assigned to Nhwa Pharmaceutical Corp · Expires 2019-10-11 · 7y expired

What this patent protects

本发明提供一种盐酸卡利拉嗪晶型Ⅳ，该晶型Ⅳ以2θ±0.2°衍射角表示的X‑射线粉末衍射谱图在4.381，6.190，9.855，13.305，13.903，15.031，16.495，17.755，19.405，22.562，24.373处显示特征峰，该晶型具有好的稳定性和溶出度。

USPTO Abstract

本发明提供一种盐酸卡利拉嗪晶型Ⅳ，该晶型Ⅳ以2θ±0.2°衍射角表示的X‑射线粉末衍射谱图在4.381，6.190，9.855，13.305，13.903，15.031，16.495，17.755，19.405，22.562，24.373处显示特征峰，该晶型具有好的稳定性和溶出度。

Drugs covered by this patent

cariprazine-hydrochloride (CARIPRAZINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN106543105B
Jurisdiction: CN
Classification: —
Expires: 2019-10-11
Drug substance claim: No
Drug product claim: No
Assignee: Nhwa Pharmaceutical Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.